首页> 美国卫生研究院文献>Iranian Journal of Pathology >Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study)

【2h】

Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study)

机译：患有出血性疾病的患者的Aryoseven安全性（重组活化因子VII）评估（上市后观察性观察研究）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background:Recombinant activated factor VII induces hemostasis in patients with coagulopathy disorders. AryoSeven™ as a safe Iranian Recombinant activated factor VII has been available on our market. This study was performed to establish the safety of AryoSeven on patients with coagulopathy disorder.

机译：背景：重组活化因子VII在凝血病患者中引起止血。 AryoSeven™作为安全的伊朗重组活化因子VII已在我们的市场上出售。进行这项研究是为了确定AryoSeven对凝血病患者的安全性。

著录项

期刊名称 Iranian Journal of Pathology
作者
Gholamreza Toogeh; Hassan Abolghasemi; Peyman Eshghi; Mohammadreza Managhchi; Mohammadreza Shaverdi-niasari; Katayoon Karimi; Samin Roostaei; Neda Emran; Alireza Abdollahi;
展开▼
作者单位

展开▼
年(卷),期 2016(11),3
年度 2016
页码 204–209
总页数 6
原文格式 PDF
正文语种
中图分类病理学;
关键词

相似文献

外文文献
中文文献
专利

1. EVALUATION OF ARYOSEVEN SAFETY (RECOMBINANT ACTIVATED FACTOR VII) IN PATIENTS WITH BLEEDING DISORDERS (AN OBSERVATIONAL POST-MARKETING SURVEILLANCE STUDY) [J] . TOOGEH GHOLAMREZA, ABOLGHASEMI HASSAN, ESHGHI PEYMAN, Iranian Journal of Pathology . 2016,第3期

机译：伴有出血性疾病的患者的芳烃安全性（重组活性因子VII）的评估（观察性标记后监测研究）
2. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders [J] . BirschmannI., KlamrothR., EichlerH., Haemophilia: the official journal of the World Federation of Hemophilia . 2013,第5期

机译：重组活化因子VII（rFVIIa）对先天性血友病伴抑制剂和其他出血性疾病的WIRK前瞻性，非干预性观察性研究结果
3. Recombinant Activated Factor VII (Eptacog Alfa Activated, NovoSeven (R)) in Patients with Rare Congenital Bleeding Disorders. A Systematic Review on its Use in Surgical Procedures [J] . Di Minno Matteo Nicola Dario, Ambrosino Pasquale, Myasoedova Veronika, Current pharmaceutical design . 2017,第7期

机译：重组活化因子VII（Eptacog Alfa活化，Novoseven）患者珍稀先天性出血障碍。对外科手术的使用系统综述
4. Toxicity Study of Recombinant Human Platelet-Derived Growth Factor-BB Hydrated Bovine Type I Collagen in Decorated Femur Model in Rabbits—a Safety Study Model for Rotator Cuff Repair [C] . YanchunLiu, Jack Ratliff, Vivek Shah, Annual meeting of the Society for Biomaterials . 2011

机译：重组人血小板衍生生长因子-BB水合牛I型胶原在家兔股骨装饰模型中的毒性研究—肩袖修复的安全性研究模型
5. A study of the increased risk of bleeding events in patients with blood clotting disorders, associated with antidepressant medication use. [D] . Ehrenborg, Adam. 2016

机译：与抗抑郁药使用相关的凝血障碍患者出血事件发生风险增加的研究。
6. Assessment of safety and efficacy of lamotrigine over the course of 1-year observation in Japanese patients with bipolar disorder: post-marketing surveillance study report Corrigendum [O] . 2017

机译：在日本双相情感障碍患者进行为期一年的观察过程中评估拉莫三嗪的安全性和有效性：上市后监测研究报告勘误
7. Long-term safety and efficacy of recombinant activated factor VII （NovoSevenⓇ） for treatment of acute bleeding episodes in congenital hemophilia with inhibitors：analysis from 10-year japanese post-marketing surveillance [O] . Akira SHIRAHATA, Mitsuhiro KUWAHARA, Katsuyuki FUKUTAKE, 2013

机译：重组活性因子VII（NovosevenⅣ）的长期安全性和疗效治疗先天性血友病患者急性出血发作：10年日本营销监测分析
8. Prolonged Prothrombin Time After Recombinant Activated Factor VII Therapy in Critically Bleeding Trauma Patients Is Associated With Adverse Outcomes. [R] . McMullin, N. R., Wade, C. E., Holcomb, J. B., 2010

机译：重组活化因子VII治疗后严重出血创伤患者的凝血酶原时间延长与不良后果相关。

Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study)

摘要

著录项

相似文献

相关主题

期刊订阅